Mohammad Hasan Sheikhha

Prof. Mohammad Hasan Sheikhha


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MGMaryam Ghasemi
Maryam Ghasemi
ERElham Roshandel
Elham Roshandel
MMMozhdeh Mohammadian
Mozhdeh Mohammadian
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
PAParvin Akbarzadehlaleh
Parvin Akbarzadehlaleh
KSKarim Shamsasenjan
Karim Shamsasenjan
Background: Over the past few years, mesenchymal stromal cells (MSCs) have attracted a great deal of scientific attention owing to their promising results in the treatment of incurable diseases. However, there are several concerns about their possible side effects after direct cell transplantation, including host immune response, time-consuming cell culture procedures, and the dependence of cell quality on the donor, which limit the application of MSCs in clinical trials. On the other hand, it is well accepted that the beneficial effects of MSCs are mediated by secretome rather than cell replacement. MSC secretome refers to a variety of bioactive molecules involved in different biological processes, specifically neuro-regeneration.Main body: Due to the limited ability of the central nervous system to compensate for neuronal loss and relieve disease progress, mesenchymal stem cell products may be used as a potential cure for central nervous system disorders. In the present study, the therapeutic effects of MSC secretome were reviewed and discussed the possible mechanisms in the three most prevalent central nervous system disorders, namely Alzheimer's disease, multiple sclerosis, and Parkinson's disease. The current work aimed to help discover new medicine for the mentioned complications.Conclusion: The use of MSC-derived secretomes in the treatment of the mentioned diseases has encouraging results, so it can be considered as a treatment option for which no treatment has been introduced so far.

2 May 2023 in International Wound Journal
Verified
Journal Article
Open access
MMMehrdad Moosazadeh Moghaddam
Mehrdad Moosazadeh Moghaddam
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
RMReza Mirnejad
Reza Mirnejad
HKHamid Kooshki
Hamid Kooshki
Antimicrobial peptides (AMPs) are among the compounds that have significant potential to deal with infectious skin wounds. Using wound dressings or skin scaffolds containing AMPs can be an effective way to overcome infections caused by antibiotic‐resistant strains. In this study, we developed an amniotic membrane‐based skin scaffold using silk fibroin to improve mechanical properties and CM11 peptide as an antimicrobial peptide. The peptide was coated on the scaffold using the soaking method. The fabricated scaffold was characterised by SEM and FTIR, and their mechanical strength, biodegradation, peptide release, and cell cytotoxicity analyses were performed. Then, their antimicrobial activity was measured against antibiotic‐resistant strains of Pseudomonas aeruginosa and Staphylococcus aureus. The in vivo biocompatibility of this scaffold was evaluated by subcutaneously implanting it under the skin of the mouse and counting lymphocytes and macrophages in the implanted area. Finally, the regenerative ability of the scaffold was analyzed in the mouse full‐thickness wound model by measuring the wound diameter, H&E staining, and examining the expression rate of genes involved in the wound healing process. The developed scaffolds exerted an inhibiting effect on the bacteria growth, indicating their proper antimicrobial property. In vivo biocompatibility results showed no significant count of macrophages and lymphocytes between the test and control groups. The wound closure rate was significantly higher in the wound covered with fibroin electrospun‐amniotic membrane loaded with 32 μg/mL CM11, where the relative expression rates of collagen I, collagen III, TGF‐β1 and TGF‐β3 were higher compared with the other groups.

5 March 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
ERElham Roshandel
Elham Roshandel
LNLeila Noorazar
Leila Noorazar
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
MMMahshid Mehdizadeh
Mahshid Mehdizadeh
MKMohammad Hossein Kazemi
Mohammad Hossein Kazemi
SPSayeh Parkhideh
Sayeh Parkhideh
Hematopoietic cancers are among the most common malignancies worldwide, which are divided into different types depending on the origin of tumor cells. In recent years, the pivotal role of different signaling pathways in the onset and progression of these cancer types has been well established. One of these pathways, whose role in blood malignancies has been well‐defined, is PI3K/mTOR/AKT axis. The signaling pathway involves in a wide variety of important biological events in cells. It is clear that dysregulation of mediators involved in PI3 kinase signaling takes a pivotal role in cancer development. Considering the undeniable role of miRNAs, as one of the well‐known families of non‐coding RNAs, in gene regulation, we aimed to review the role of miRNAs in regulation of PI3 kinase signaling effectors in hematopoietic cancers.

21 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAmin Ebrahimi Sadrabadi
Amin Ebrahimi Sadrabadi
ABAhmad Bereimipour
Ahmad Bereimipour
AJArsalan Jalili
Arsalan Jalili
MGMazaher Gholipurmalekabadi
Mazaher Gholipurmalekabadi
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
Alexander Marcus SeifalianAlexander Marcus Seifalian
Alexander Marcus Seifalian
COVID 19 disease has become a global catastrophe over the past year that has claimed the lives of over two million people around the world. Despite the introduction of vaccines against the disease, there is still a long way to completely eradicate it. There are concerns about the complications following infection with SARS-CoV-2. This research aimed to evaluate the possible correlation between infection with SARS-CoV viruses and cancer in an in-silico study model. To do this, the relevent dataset was selected from GEO database. Identification of differentially expressed genes among defined groups including SARS-CoV, SARS-dORF6, SARS-BatSRBD, and H1N1 were screened where the |Log FC| ≥ 1and p < 0.05 were considered statistically significant. Later, the pathway enrichment analysis and gene ontology (GO) were used by Enrichr and Shiny GO databases. Evaluation with STRING online was applied to predict the functional interactions of proteins, followed by Cytoscape analysis to identify the master genes. Finally, analysis with GEPIA2 server was carried out to reveal the possible correlation between candidate genes and cancer development. The results showed that the main molecular function of up- and down-regulated genes was “double-stranded RNA binding” and actin-binding, respectively. STRING and Cytoscape analysis presented four genes, PTEN, CREB1, CASP3, and SMAD3 as the key genes involved in cancer development. According to TCGA database results, these four genes were up-regulated notably in pancreatic adenocarcinoma. Our findings suggest that pancreatic adenocarcinoma is the most probably malignancy happening after infection with SARS-CoV family.

1 January 2024 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
MMMozhdeh Mohammadian
Mozhdeh Mohammadian
MSMaryam Salimi
Maryam Salimi
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
LNLeila Noorazar
Leila Noorazar
MGMahmoud Dehghani Ghorbi
Mahmoud Dehghani Ghorbi
AHAbbas Hajifathali
Abbas Hajifathali
B‐cell chronic malignancies, including chronic lymphocytic leukemia and lymphomas, are among the most common blood malignancies. Conventional therapies for these lymphoproliferative diseases include chemotherapy and radiotherapy. However, treating these types of cancer is still challenging due to developing resistance to chemotherapy drugs and even novel agents like immunochemotherapy. Therefore, many studies are underway to clarify the mechanisms involved in this phenomenon. Recently, the role of noncoding RNAs in regulating gene expression has been well documented in the literature. microRNAs are small noncoding RNAs that regulate gene expression at transcriptional and posttranscriptional levels. Long noncoding RNAs are involved in cell differentiation and tissue development via transcriptional and posttranscriptional regulation. Several miRNAs regulate B‐cell development and stimulate activation in normal or malignant B‐cells. Molecular assessments revealed the relationship between the up/downregulation of different genes and the development of therapeutic resistance. Studies suggest that the dysregulation of these molecules could be the missing link in developing resistance to chemotherapy drugs. Serum levels of miRNAs can be employed as a predictive biomarker for diagnosis, prognosis, and response to treatment in B‐cell malignancies. This study reviews the role of different microRNAs and long noncoding RNAs in regulating the expression of genes involved in drug resistance in B‐cell chronic lymphocytic leukemia and lymphomas.

6 October 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
MMMahshid Mehdizadeh
Mahshid Mehdizadeh
MSMohammad Hasan Sheikhha
Mohammad Hasan Sheikhha
MNMaryam Nikoonezhad
Maryam Nikoonezhad
GSGhazaleh Sankanian
Ghazaleh Sankanian
MSMasoud Soleimani
Masoud Soleimani
ASArezou Sayad
Arezou Sayad
Multiple myeloma is one of the most hard-to-treat cancers among blood malignancies due to the high rate of drug resistance and relapse. The researchers are trying to find more effective drugs for treatment of the disease. Hence, the use of drugs targeting signaling pathways has become a powerful weapon. Overactivation of phosphatidylinositol 3-kinase signaling pathways is frequently observed in multiple myeloma cancer cells, which increases survival, proliferation, and even drug resistance in such cells. In recent years, drugs that inhibit the mediators involved in this biological pathway have shown promising results in the treatment of multiple myeloma. In the present study, we aimed to introduce phosphatidylinositol 3-kinase signaling inhibitors which include small molecules, herbal compounds, and microRNAs.